Adapalane: A review of its use in the treatment of acne vulgaris

Drugs

Volumn 64, Issue 13, 2004, Pages 1465-1478

  Waugh, John ^a   Noble, Stuart ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acne vulgaris; Adapalene; Pharmacodynamics; Pharmacokinetics; Therapeutic efficacy; Tolerability

Indexed keywords

ADAPALENE; ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; CLINDAMYCIN; CYCLINE; LYMECYCLINE; MINOCYCLINE; O DEMETHYLASE; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; TAZAROTENE; DERMATOLOGICAL AGENT; NAPHTHALENE DERIVATIVE;

ACNE VULGARIS; ANTIMICROBIAL ACTIVITY; BURNING SENSATION; CELL DIFFERENTIATION; CLINICAL TRIAL; DESQUAMATION; DRUG ABSORPTION; DRUG BINDING; DRUG CONJUGATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HYDROXYLATION; DRUG INDICATION; DRUG TOLERABILITY; DRUG USE; DRY SKIN; ERYTHEMA; HUMAN; HYPERPIGMENTATION; KERATINIZATION; META ANALYSIS; PATIENT COMPLIANCE; PRURITUS; REVIEW; SKIN IRRITATION; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; GEL; INTRADERMAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; DERMATOLOGIC AGENTS; GELS; HUMANS; NAPHTHALENES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 3242807326     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464130-00005     Document Type: Review

References (64)

1. Bergfeld WF. Topical retinoids in the management of acne vulgaris. J Drug Dev Clin Pract 1996 Dec; 8: 151-60
2. Strasburger VC. Acne: what every pediatrician should know about treatment. Pediatr Clin North Am 1997; 44 (6): 1505-23
3. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003; 63 (15): 1579-96
4. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003 Jul; 49 (1): S1-38
5. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003 Sep; 49 (3): S200-10
6. Webster GF. Acne vulgaris. BMJ 2002; 325: 475-8
7. Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol 2003 Jul; 49 (1): 83-90
8. Brogden RN, Goa KL. Adapalene: a review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997 Mar; 53 (3): 511-9
9. Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 1998 Aug; 39 (2 Pt 3): S17-24
10. Galderma Laboratories. Differin (adapalene) gel, 0.1%. Product insert information, United States [online]. Available from URL: http://www.differin. com/about/insertadapalenegel. shtml [Accessed 2004 May 4]
11. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997; 36 (6 Suppl.): S96-103
12. Anonymous. Adapalene for acne. Med Lett Drugs Ther 1997; 39 (995): 19-20
13. Galderma Laboratories. Differin® (adapalene) cream 0.1% product insert information, United States [online]. Available from URL: http://www.differin.com/about/insertadapalene cream.shtml [Accessed 2004 May 4]
14. Caron D, Clucas A, Dunsire JP, et al. Radiolabelled adapalene is poorly absorbed after topical application of adapalene 0.1% gel. J Eur Acad Dermatol Venerol 1998 Sep; 11 Suppl. 2: 275-6
15. Medsafe. Information for Health Professionals: data sheet. Differen™ adapalene 0.1% [online]. Available from URL: http:// www.medsafe.govt.nz/Profs/Datasheet/d/Differingel.htm [Accessed 2004 May 28]
16. Tu P, Li GQ, Zhu XJ, et al. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 31-6
17. Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998 Oct; 139 Suppl. 52: 41-7
18. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998 Oct; 139 Suppl. 52: 26-33
19. Cunliffe WJ, Caputo R, Dreno B, et al. Efficacy and safety comparison of adapalene (CD271) gel and tretinoin gel in the topical treatment of acne vulgaris: a European multicentre trial. J Dermatol Treat 1997; 8 (3): 173-8
20. Alirezai M, Meynadier J, Jablonska S, et al. Efficacy and safety comparison study of 0.1% and 0.03% adapalene gels and tretinoin gel in the topical treatment of acne [in French]. Ann Dermatol Venereol 1996; 123 (3): 165-70
21. Shalita A, Weiss J, Chalker D, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996 Mar; 34 (3): 482-5
22. Verschoore M, Langner A, Wolska H, et al. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol 1991 Apr; 124: 368-71
23. Cunliffe WJ, Danby FW, Dunlap F, et al. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002; 12 (4): 350-4
24. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002 Sep; 147 (3): 523-7
25. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat 2001 Sep; 12 (3): 149-57
26. Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001 Oct; 68 (4 Suppl.): 10-9
27. Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001 Jun; 67 (6 Suppl.): 10-6
28. Webster G, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison of the efficacy and tolerability of treating facial acne vulgaris once daily with tazarotene 0.1% gel or adapalne 0.1% gel. Cutis 2002; 69: 4-11
29. Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003 Sep; 49 (3 Suppl.): S218-26
30. Wolf Jr JE, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003 Sep; 49 (3 Suppl.); S211-7
31. Campo M, Zuluaga A, Escobar P, et al. A comparative study on the effectiveness of lymecicline and adapalene versus minocicline and adapalene in the treatment of acne vulgaris. Ann Dermatol Venereol 2002 Jul; 129 (Suppl.): 371
32. Zhang J, Feng LL, Teng TY, et al. The maintenance effect of a treatment with adapalene gel 0.1% in patients with acne vulgaris previously treated with clindamycin topical solution, 1% alone or in combination with adapalene gel, 0.1% [poster]. The American Academy Of Dermatology 62nd Annual Meeting; 2004 Feb 6-11; Washington, DC
33. Fang L, Fu W, Gu J, et al. Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris [abstract no. P0020]. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: 374
34. Campo MH, Zuluaga A, Escobar P, et al. Efficacy and safety comparison of lymecycline associated with adapalene and minocycline associated with adapalene in the treatment of acne vulgaris [poster]. 20th World Congress of Dermatology; 2002 Jul 1-5; Paris
35. Burke BM, Cunliffe WJ. The assessment of acne vulgaris: the Leeds technique. Br J Dermatol 1984 Jul; 111(1): 83-92
36. Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 37-42
37. Miyachi Y, Kawashima M, Harada S. Efficacy and safety of 0.1% and 0.03% adapalene gel or vehicle in Japanese subjects with acne [abstract no. P0049]. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: S380
38. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1 % gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998 Oct; 139 Suppl. 52: 48-56
39. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S126-34
40. Cunliffe WJ, Orfanos C, Caputo R, et al. Comparison of clinical safety and efficacy of adapalene gel and tretinoin gel in the treatment of acne vulgaris [abstract no. P139]. J Eur Acad Dermatol Venereol 1995 Oct; 5 Suppl. 1: S152
41. Cunliffe WJ, Gollnick H. Currents concepts in the treatment of acne vulgaris [abstract], European Academy of Dermatology and Venereology Annual Meeting; 2000 Oct 11-15; Geneva
42. Egan N, Loesche MC, Baker MM. Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001 Oct; 68 (4 Suppl.): 20-4
43. Dunlap FE, Mills OH, Tuley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998 Oct; 139 Suppl. 52: 17-22
44. Savin R, Berger R. A split-face study to compare the safety and efficacy of Avita™ (tretinoin cream) cream 0.025% and Differin™ (adapalene gel) gel 0.1 % in subjects with grade II or III acne vulgaris [abstract no. 065]. American Academy of Dermatology 57th Annual Meeting; 1999 Mar 19-24; New Orleans, 65
45. Caron D, Sorba V, Kerrouche N, et al. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S110-2
46. Verschoore M, Poncet M, Czernielewski J, et al. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S104-9
47. Cunliffe WJ. European multicentre study of adapalene versus tretinoin gel [abstract]. Br J Dermatol 1996 Jul; 135 Suppl. 47: 29
48. Baker M, Tuley M, Busdiecker FL. Adapalene gel 0.1% is effective and well tolerated in acne patients in a dermatology practice setting. Cutis 2001 Oct; 68 (4 Suppl.): 41-7
49. Queille-Roussel C, Poncet M, Mesaros S, et al. Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel. Clin Ther 2001 Feb; 23 (2): 205-12
50. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1 % gel and six different tretinoin formulations. Br J Dermatol 1998 Oct; 139 Suppl. 52: 34-40
51. Caron D, Sorba V, Clucas A, et al. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S113-5
52. Greenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis 2003 Jul; 72 (1): 76-81
53. Toole JWP, Lockhart L, Potrebka J, et al. Comparative irritancy study among retinoid creams and gels. J Cutan Med Surg 1999 Oct; 3 (6): 298-301
54. Dosik JS, Arsonnaud S. Determination of the cumulative irritation potential of adapalene cream and gel 0.1% compared to tretinoin micro, 0.04% amd micro 0.1% after repeated applications to the skin of healthy subjects [poster]. American Academy of Dermatology 62nd Annual Meeting; 2004 Feb 6-11; Washington, DC
55. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis 2001 Oct; 68 (4 Suppl.): 48-54
56. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1 % versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003 Sep; 49 (3 Suppl.); S227-32
57. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1 % gel versus tretinoin 0.025% in patients with acne vulgaris: a meta-analysis of five randomized trials. J Eur Acad Dermatol Venerol 1998 Sep; 11 Suppl. 2: 189
58. Galderma Laboratories. Differin (adapalene solution) solution, 0.1%. Product insert information. United States [online]. Available from URL: http://www.differin.com/about/ insertadapalenesolution.shtml [Accessed 2004 May 4]
59. Bershad SV. The modern age of acne therapy: a review of current treatment options. Mt Sinai J Med Sep-Oct 2001; 68 (4-5): 279-86
60. Goodman GJ. Acne and acne scarring: why should we treat? Med J Aust 1999; 171 (2): 62-3
61. Cotterill JA, Cunliffe WJ. Suicide in dermatalogical patients. Br J Dermatol 1997 Aug; 137 (2): 246-50
62. Krowchuk DP. Managing acne in adolescents. Pediatr Clin North Am 2000 Aug; 47 (4): 841-57
63. Clark SM, Cunliffe WJ, Katsambas AD. Childhood/adolescent acne: a review of aetiology and management. Curr Paediatr 1999; 9 (1): 1-6
64. The treatment of acne vulgaris: an update. Merec Bull 1999; 10 (8): 29-32